Characteristics of patients undergoingHLA-matched bone marrow or peripheral blood progenitor cell transplantation
| SPN . | Age (y) . | Sex . | Diagnosis . | Transplant type . | Preparatory regimen . | Donor-patient KIR compatibility . | GVHD . | Status at last follow-up . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Group 1 | ||||||||||
| 1899 | 48 | F | CML | CP | MRD | BM | FTBI/VP16 | KIR-mismatched | None | Alive and CCR |
| 2017 | 21 | F | CML | CP | MRD | BM | FTBI/VP16 | KIR-mismatched | None | Alive and CCR |
| 1991 | 42 | F | CML | CP | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD I (skin) | Alive and CCR |
| 2025 | 29 | F | CML | CP | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD I-II (skin) | Alive and CCR |
| 2060 | 47 | F | AML | CR | MRD | BM | FTBI/VP16 | KIR-mismatched | None | Alive and CCR |
| 2036 | 38 | F | AML | CR | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD (skin) | Alive and CCR |
| 2067 | 42 | M | CML | AP | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD I (skin); cGVHD (eyes, mouth, skin) | Alive and CCR |
| 2138 | 32 | F | CML | CP | MRD | PBPC | BU/CY | KIR-mismatched | None | Alive and CCR |
| Group 2 | ||||||||||
| 1920 | 23 | M | CML | AP | MRD | BM | FTBI/VP16/CY | KIR-mismatched | None | Alive and CCR |
| 1970 | 56 | F | AML | CR2 | MRD | BM | BU/VP16/CY | KIR-mismatched | None | Died day 741, meningitis |
| 2040 | 53 | F | AML | IF | MRD | BM | BU/VP16/CY | KIR-mismatched | cGVHD (liver) | Rel day 228; died day 280 |
| 2068 | 39 | M | CML | AP | MRD | BM | BU/CY | KIR-mismatched | None | Alive and CCR |
| 2089 | 34 | F | CML | CP | MRD | PBPC | BU/CY | KIR-matched | None | Alive and CCR |
| Nongroup 1 and 2 | ||||||||||
| 1980 | 30 | F | CML | CP | MUD | BM | FTBI/CY | KIR-mismatched | None | Rel day 737; given DLI |
| 2038 | 27 | M | AML | CR1 | MRD | PBPC | FTBI/VP16 | KIR-mismatched | cGVHD (eyes, mouth, liver) | Alive and CCR |
| 2061 | 48 | M | CML | AP | MRD | PBPC | BU/CY | KIR-mismatched | cGVHD (mouth, eye); aGVHD I (skin); aGVHD IV (liver, gut) | Died day 159-aGVHD |
| 2062 | 45 | M | CML | CP | MRD | BM | BU/CY | KIR-matched | None | Rel day 180; retranspl |
| 2140 | 41 | F | AML | IF | MRD | PBPC | FTBI/VP16/CY | KIR-matched | cGVHD (extensive) | Alive and CCR |
| SPN . | Age (y) . | Sex . | Diagnosis . | Transplant type . | Preparatory regimen . | Donor-patient KIR compatibility . | GVHD . | Status at last follow-up . | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Group 1 | ||||||||||
| 1899 | 48 | F | CML | CP | MRD | BM | FTBI/VP16 | KIR-mismatched | None | Alive and CCR |
| 2017 | 21 | F | CML | CP | MRD | BM | FTBI/VP16 | KIR-mismatched | None | Alive and CCR |
| 1991 | 42 | F | CML | CP | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD I (skin) | Alive and CCR |
| 2025 | 29 | F | CML | CP | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD I-II (skin) | Alive and CCR |
| 2060 | 47 | F | AML | CR | MRD | BM | FTBI/VP16 | KIR-mismatched | None | Alive and CCR |
| 2036 | 38 | F | AML | CR | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD (skin) | Alive and CCR |
| 2067 | 42 | M | CML | AP | MUD | BM | FTBI/CY | KIR-mismatched | aGVHD I (skin); cGVHD (eyes, mouth, skin) | Alive and CCR |
| 2138 | 32 | F | CML | CP | MRD | PBPC | BU/CY | KIR-mismatched | None | Alive and CCR |
| Group 2 | ||||||||||
| 1920 | 23 | M | CML | AP | MRD | BM | FTBI/VP16/CY | KIR-mismatched | None | Alive and CCR |
| 1970 | 56 | F | AML | CR2 | MRD | BM | BU/VP16/CY | KIR-mismatched | None | Died day 741, meningitis |
| 2040 | 53 | F | AML | IF | MRD | BM | BU/VP16/CY | KIR-mismatched | cGVHD (liver) | Rel day 228; died day 280 |
| 2068 | 39 | M | CML | AP | MRD | BM | BU/CY | KIR-mismatched | None | Alive and CCR |
| 2089 | 34 | F | CML | CP | MRD | PBPC | BU/CY | KIR-matched | None | Alive and CCR |
| Nongroup 1 and 2 | ||||||||||
| 1980 | 30 | F | CML | CP | MUD | BM | FTBI/CY | KIR-mismatched | None | Rel day 737; given DLI |
| 2038 | 27 | M | AML | CR1 | MRD | PBPC | FTBI/VP16 | KIR-mismatched | cGVHD (eyes, mouth, liver) | Alive and CCR |
| 2061 | 48 | M | CML | AP | MRD | PBPC | BU/CY | KIR-mismatched | cGVHD (mouth, eye); aGVHD I (skin); aGVHD IV (liver, gut) | Died day 159-aGVHD |
| 2062 | 45 | M | CML | CP | MRD | BM | BU/CY | KIR-matched | None | Rel day 180; retranspl |
| 2140 | 41 | F | AML | IF | MRD | PBPC | FTBI/VP16/CY | KIR-matched | cGVHD (extensive) | Alive and CCR |
SPN indicates Stanford patient number; F, female; M, male; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; CP, chronic phase; AP, accelerated phase; CR, complete remission; IF, induction failure; MRD, matched related donor; MUD, matched unrelated donor; BM, bone marrow; PBPC, peripheral blood progenitor cell; FTBI, fractionated total body irradiation; VP16, etoposide; CY, cyclophosphamide; BU, busulfan; GVHD, graft-versus-host disease; aGVHD, acute GVHD; cGVHD, chronic GVHD; CCR, continuous complete remission; Rel, relapse; DLI, donor leukocyte infusion; retranspl, retransplanted. Patients in groups 1, 2, and nongroup 1 and 2 are separated into sections.